Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 11/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820427 | 0.78 | LPL (0.40) | FFAR1LPLLIPGIRAK4 | |
| SCHEMBL18555496 | 0.76 | NPC1 (0.46) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL31221572 | 0.75 | FFAR1 (0.44) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL17492388 | 0.74 | LPL (0.46) | FFAR1LPLLIPGIRAK4 | |
| SCHEMBL29707248 | 0.73 | FFAR1 (0.43) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL31731056 | 0.72 | FFAR1 (0.41) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL18247818 | 0.71 | FFAR1 (0.40) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL30182177 | 0.71 | ALKBH2 (0.46) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL5928218 | 0.71 | ALKBH2 (0.46) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL23881423 | 0.70 | CDK2 (0.42) | FFAR1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260109696-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260078116-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-11-06 | — | — | US | disclosed |
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-10-07 | — | — | US | disclosed |
| WO-2025007863-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-119241532-A | 1H-pyrazolo [4,3-c ] pyridine compound, composition and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2016142310-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-15 | — | — | WO | disclosed |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
| WO-2016090296-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | ANANTHAN SUBRAMANIAM (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| EP-2970311-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | The Brigham and Women's Hospital, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | FFAR1 4008/4885LPL 3052/4885LIPG 2352/4885 |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | FFAR1 4008/4885LPL 3052/4885LIPG 2352/4885 |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | BMP1, BMPR2, BMP2 | FFAR1 2354/4885LPL 156/4885LIPG 91/4885 |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | FFAR1 4008/4885LPL 3052/4885LIPG 2352/4885 |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | FFAR1 4008/4885LPL 3052/4885LIPG 2352/4885 |
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | FFAR1 4604/4885LPL 4016/4885LIPG 3830/4885 |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SLC18A2, SLC6A2, SLC6A3 | FFAR1 921/4885LPL 2267/4885LIPG 3621/4885 |
| US-20260078116-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, MCL1 | FFAR1 4107/4885LPL 3873/4885LIPG 3675/4885 |
| US-20260109696-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | KRAS, MYC, NRAS | FFAR1 4194/4885LPL 3678/4885LIPG 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.